Novartis Deal Sealed, Vanda Plays Up Injectable Potential
This article was originally published in The Pink Sheet Daily
Executive Summary
Vanda turns near-rags to riches selling Fanapt rights back to the originator, a rare feat for a drug in-licensed from Big Pharma.